- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Neovascular age-related macular degeneration, using a port delivery system
- Meeting Date: March 2022
- Public Summary Document (PSD) March 2022 – May 2026 PBAC Meetings - (PDF)
- Public Summary Document (PSD) March 2022 – May 2026 PBAC Meetings - (DOCX)
Ranibizumab – March 2022 – May 2026
Solution for ocular implant 39.5 mg in 0.395 mL
Last updated
14 September 2026